Navigation Links
Oncolytics Biotech Inc. Transfers 40-Litre cGMP Manufacturing Process for REOLYSIN(R)
Date:5/22/2008

ech.com" target="_new">http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the manufacturing process, sufficiency of the 40-litre scale and commercialization, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 27th U.S. Patent
2. Oncolytics Biotech Inc. Collaborators to Present Phase II Sarcoma Trial Results at ASCO Annual Meeting
3. Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
4. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
5. Oncolytics Biotech Inc. Announces Details of 2008 Annual Shareholder Meeting
6. Oncolytics Biotech Inc. Announces 2008 First Quarter Results
7. Oncolytics Biotech Inc. Announces Journal of Immunology Publication on Reovirus Activation of Dendritic Cells
8. Oncolytics Biotech Inc. Announces Gene Therapy Publication on Reovirus Treatment for Melanoma
9. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting
10. Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting
11. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... DNA Genotek, a leading provider of products for...t Tepnel Pharmaceutical Services will offer Oragen...ucleic acid extraction and genotyping service. , ...r 1, 2009 -- DNA Genotek , a leading provider of ...nnounced that Tepnel Pharmaceutical Services wil...
(Date:12/1/2009)... The two humanitarian organizations will collabo... biomedical repair technologies. Their shared effo... country of Togo. , Dalla...signing of a Memorandum of Understanding, Mercy Sh...artnership to help develop sustainable infrastruct...
(Date:12/1/2009)... California waste-to-energy firm claims first pl...eration, smallest footprint, salable pure gas, byp... (PRWEB) December 15, 2009 -- The ...tive organic waste-to-energy process will take pla...uary. , , ,This biowaste process known as VRAD&co...
(Date:11/30/2009)...Ohio, Nov. 30 The Ohio Capital Fun...ion,s first minority business early-stage capital ...ber 3, is called "Transforming the Landscape of Bu... Capital Summit." It will feature several speakers...eaders and local minority entrepreneurs. ,, "T...
Breaking Biology Technology:Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 2Tepnel Pharmaceutical Services to Offer DNA Genotek's Sample Collection Kit in its Nucleic Acid Extraction and Genotyping Service 3Mercy Ships and MediSend International Partner to Deliver Hope and Healing 2Mercy Ships and MediSend International Partner to Deliver Hope and Healing 3First Public Showing of Innovative Waste-to-Energy Process 2Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2
...Jersey, December 5, Rosetta Genomics, Ltd. (NASDAQ...pany leveraging microRNAs as biomarkers,reported t...arter ended,September 30, 2008 and business highli...e third quarter of 2008 of $705,000.,These revenue...rkway Clinical,Laboratories at the end of July thr...
...c.,(Nasdaq: MDVN ) today announced that David Hu...ill be a featured speaker on two panels at the RBC...rsday, December 11, in New York: , -- "Wagin...tern Time, -- "The Challenge of Alzheimer,s Dis... A live audio webcast of each panel will be ...
... 4 Octapharma,Chairman Wolfgang Marguerre today a...o lead Octapharma,s plasma operations in the Unite...counsel since 2002 and will now serve as,President...ivate plasma products company in the world, Octaph...nta company that operates 12,plasma centers in the...
Other Biology Technology:Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 2Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 3Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 4Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 5Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 6Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 7Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 8Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 9Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 10Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference 2Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations 2
(Date:11/30/2009)...roteins are crucial for infection. Each binds a sp...ch stimulates the host cell to take up the pathoge...erent function, for example the regulation of cell...e now been published in the current issue of the "...is one of the sources for Listeria infections le...
(Date:11/30/2009)...stress of seeing your extended family over the hol...ch report in the December 2009 print issue of the ...io.org ) shows that you might be right. Here,s the... to entirely new treatments that help keep autoimm...er control. That,s because researchers from the Un...
(Date:11/26/2009)...me of the Ocean,s most distinctive residents. ,Eve...ge head shape, says Michelle McComb from Florida ...ark,s vision. ,Perhaps their visual field has been... giving the sharks excellent stereovision and dept...were two schools of thought on this theory. In 194...
Breaking Biology News(10 mins):It takes 2 to infect 2Seeing family for the holidays? Scientists discover how the stress might kill you 2Wide heads give hammerheads exceptional stereo view 2The Chopra Center Press Set to Release New Book this June 25 49801 1The Chopra Center Press Set to Release New Book this June 25 49801 2The Chopra Center Press Set to Release New Book this June 25 49801 3A Canada wide technology platform for mapping the human interactome 8974 1A Canada wide technology platform for mapping the human interactome 8974 2Video 3A Gabrielle Reece Shows Natural is Beautiful in New PureVia 28TM 29 Campaign 49795 1Video 3A Gabrielle Reece Shows Natural is Beautiful in New PureVia 28TM 29 Campaign 49795 2Video 3A Gabrielle Reece Shows Natural is Beautiful in New PureVia 28TM 29 Campaign 49795 3
...Researchers at New York University,s Courant Insti... algorithm that enhances the ability to detect a c...p the set of tumor-suppressor genes involved in lu...,s gene-chips that can scan hundreds of patients, ...he findings will appear in the July issue of the A...
...Knee cartilage injuries can be effectively repaire...t stop the regeneration process concludes research... The study, "Maturation of tissue engineered carti... knees", published in the July 2006 (Volume 12, Nu...that engineered cartilage tissue can grow and matu...
...Bacteria like Salmonella have a complicated immune...ign DNA trying to invade their cell membrane, acco...he June 8 issue of Science Express. The research, ...l Cancer Center in San Diego, could have major imp...se-causing bacteria. The findings may also impact ...
Other Biology News:NYU algorithm enhances ability to detect cancer genes 2NYU algorithm enhances ability to detect cancer genes 3Bacteria have their own immune system protecting against outside DNA 2
Sheep Anti-Human Vesicle Associated Membrane Protein (VAMP 1/2) Polyclonal Antibody, Unconjugated from Exalpha Biologicals, Inc.
Rat Anti-Mouse TCR, Va 2 Monoclonal Antibody, Unconjugated, Clone B20.1 from CEDARLANE Laboratories Limited
Feline IFN-alpha, Unconjugated from R&D Systems
...A Development kit contains the basic components re...easure natural and recombinant canine Monocyte Che...tes and serum.1 Each kit contains sufficient mater...l plates, provided that the following conditions a...
Biology Products: